Q1 EPS Forecast for Emergent BioSolutions Lowered by Analyst

Emergent BioSolutions Inc. (NYSE:EBS) – Equities research analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Emergent BioSolutions in a research report issued on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.86 per share for the quarter, down from their previous forecast of $0.87. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q3 2026 earnings at $1.10 EPS.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.22. The firm had revenue of $222.20 million during the quarter, compared to analyst estimates of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%.

Separately, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Stock Up 21.2%

Emergent BioSolutions stock opened at $6.66 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock has a market capitalization of $361.22 million, a PE ratio of -1.62 and a beta of 2.09. The business has a 50 day simple moving average of $5.16 and a 200-day simple moving average of $7.79. Emergent BioSolutions has a 12 month low of $4.02 and a 12 month high of $15.10.

Institutional Investors Weigh In On Emergent BioSolutions

A number of large investors have recently modified their holdings of EBS. Covestor Ltd lifted its stake in shares of Emergent BioSolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Emergent BioSolutions in the 4th quarter valued at about $63,000. Corton Capital Inc. purchased a new position in Emergent BioSolutions in the 1st quarter worth approximately $70,000. EP Wealth Advisors LLC boosted its holdings in shares of Emergent BioSolutions by 33.1% during the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,790 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Emergent BioSolutions by 40.4% in the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 4,894 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.20% of the stock is currently owned by insiders.

Emergent BioSolutions announced that its board has approved a stock repurchase plan on Monday, March 31st that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire up to 19% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.